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A study to assess the impact of immunotherapy with Mycobacterium vaccae on the treatment of pulmonary 
tuberculosis was conducted under existing conditions in Kano, a large city in Northern Nigeria. Whilst it did 
not quite meet all the criteria of a well-controlled randomized or double-blind trial, the study produced results 
suggestive of a successful intervention. Immunotherapy with M. vaccae had a beneficial influence on clinical 
recovery and survival, whether given after 1,2 or 3 weeks of chemotherapy, according to an assessment made 
l&14 months after treatment. 
Approximately 3 weeks (19.8 days) after the onset of chemotherapy (SHRZ), 73% of the patients who 
received immunotherapy and 19% of those who received placebo (chemotherapy alone) had become sputum 
negative by microscopy for acid-fast bacilli (AFB). Similarly, a mean fall in erythrocyte sedimentation rate 
(ESR) of 25.4 * 2.50 mm and 4.0 f 2.29 mm was observed in the immunotherapy and placebo recipients 
respectively, at the same time of assessment. When weight was assessed in the two groups, it was observed that 
3 weeks after starting chemotherapy, the recipients of immunotherapy had a mean weight gain of 
2.90 f 0.24 kg whilst placebo recipients had a mean weight gain of only 0.55 f 0.17 kg. 
These parameters were re-evaluated, l&14 months later. They showed that 11% of the recipients of the 
active intervention and 84.6% of placebo recipients still had demonstrable AFB in their sputum. The mean 
weight gain had increased to 7.91 * 1.03 kg and 2.04 f 0.94 kg in the immunotherapy and placebo recipients 
respectively. The recorded mortality amongst those traced in this second follow-up was 40% for the placebo 
recipients and 0% for the recipients of immunotherapy. 
The impact of immunotherapy is discussed against the backdrop of a high mortality rate from tuberculosis, 
resulting from the absence of the most basic of anti-TB medication in the hospital, a preponderance of 
fake drugs in the open markets and local chemist stores as well as the rising seroprevalence of HIV and 
AIDS. 
Introduction 
The incidence of tuberculosis is high throughout 
Africa, especially in the sub-Saharan region, where 
the situation is rapidly worsening (1,2). Current 
problems affecting the control of tuberculosis include 
the world recession which is limiting funds available 
for health care (3), and the epidemic of human 
immunodeficiency virus (HIV) infection acting as a 
major risk factor for tuberculosis (4-6). Thus 
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national health services are unable to meet the 
demands of a rising incidence of tuberculosis with 
the long treatment period it requires. The situation 
would be altered radically if the period of chemo- 
therapy could be reduced by the introduction of an 
immunotherapeutic step, obviating the need for the 
continuation phase of treatment (7). The continu- 
ation phase of therapy is aimed at overcoming 
persister bacilli, which are in a state of altered 
metabolism unaffected by drugs. This persistence is 
partly due to the nature of the organism and partly 
to the failure of the host’s immune mechanisms to 
return to a state of antibacterial immunity, even 
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after substantial reduction of bacillary and antigenic 
loads. 
Preliminary studies in the Middlesex Hospital, 
London (S), Kuwait (9,10), and The Gambia (11) 
indicated that injection of a suspension of killed 
Myobacterium vaccae 4-6 weeks after the onset of 
chemotherapy, may have the effects required of a 
potential immunotherapeutic agent (7,12). In this 
study, we have assessed this preparation under the 
typical adverse conditions prevalent in regions where 
such therapy is needed most. The normal practices of 
the investigating institution were disrupted as little as 
possible, the exceptions being the administration of 
immunotherapy or placebo, additional investiga- 
tions, and attempting follow-up about 1 yr after 
diagnosis. 
The city of Kano on the edge of the Sahel in 
Northern Nigeria has a population of about three 
million, and tuberculosis is a common disease. The 
state provides free anti-tuberculosis chemotherapy 
when available. However, the Infectious Diseases 
Hospital frequently has no stocks, with the occa- 
sional exception of streptomycin. Thus, the pre- 
scribed medication is frequently bought from private 
pharmacies at prices usually beyond the patients’ 
means. The quality of purchased drugs is uncertain 
and they are often fake, diluted, or outdated 
(3,13,14). This results in many patients receiving 
treatment for only a few weeks, and very high rates of 
treatment failure and death are observed. 
Materials and Methods 
PATIENTS 
The patients used in this study were those who 
presented at the Infectious Diseases Hospital, Kano, 
with symptoms of pulmonary tuberculosis, and in 
whose unconcentrated sputum, acid-fast bacilli could 
be seen after staining by the Ziehl-Neelsen method. 
All were aged 18 years or above and entered the 
study between December 1990 and April 1991 after 
informed consent. All patients were counselled and 
gave their consent prior to HIV testing. Each patient 
was weighed and clinically examined, and chest X-ray 
was obtained from 75 patients. The limitation was 
the availability of X-ray films. The majority of 
patients who had chest X-ray examinations showed 
evidence of advanced bilateral tuberculosis, mostly 
with cavities. Gross weight loss and a history of 
chronic cough and haemoptysis were common at 
presentation. Many were brought to hospital having 
collapsed at home or on the streets. Blood samples 
were taken for blood count and erythrocyte sedimen- 
tation rate (ESR), and serum was stored at - 20°C 
for later serological studies. Each patient was pre- 
scribed a 2 month course of daily chemotherapy with 
streptomycin (1 g IM), rifampicin (450 mg), isoniazid 
(300 mg) and pyrazinamide (1.5 g), followed by a 
daily 6 month continuation phase of rifampicin 
(450 mg), and isoniazid (300mg). Most patients 
could afford only a few weeks’ supply of drugs at a 
time. Patients who did not receive daily chemo- 
therapy from diagnosis to the point at which immu- 
notherapy or placebo was instituted, were excluded 
from the study. One hundred and eighty randomized 
patients were recruited. Due to their level of debility, 
60 patients (43 placebo recipients and 17 M. vaccae 
recipients) from the 180 patients who were random- 
ized, remained in hospital for l-2 weeks, but most 
recruited patients were given ambulatory care. This 
did not have implications for their therapy, since at 
this point the hospital did not have any stocks of 
anti-TB drugs except for streptomycin. Dependent 
upon supplies, some patients benefited from a vari- 
able amount of free streptomycin and others did not. 
However, all recruited patients who did not receive 
the free supply of streptomycin were made to pur- 
chase at least 1 month’s worth from the local chemist 
shops. Consequently, inpatient care did not result in 
privileged chemotherapy. These inpatients, like their 
counterparts who received ambulatory treatment, 
purchased drugs from local pharmacy stores and thus 
had equal chances of obtaining fake medications. It is 
important to note that prior to recruitment into the 
study, pill-counting ensured that patients had at least 
1 month’s worth of SHRZ. 
STUDY DESIGN 
The study was a single-blind randomized placebo 
controlled trial. The difference in the inflammatory 
response provoked by the placebo (normal saline) 
and the M. vaccae, and the logistical requirements of 
a double-blind trial, argued in favour of a single- 
blind trial. Clinical assessment was by the principal 
investigator (PCO) and two other medical officers. 
All three were generally unaware of the grouping, but 
sometimes the site of injection will have been seen. 
However, the endpoints of the trial were assessed by 
health care workers who were definitely blind to the 
intervention given. Thus, microbiological examina- 
tion of sputum, ESR estimation, follow-up patient 
tracing and weight measurements were carried out by 
staff unaware of which patients had received the 
active preparation. 
Primary outcome 
Sputum smear conversion at 1 month and at 1 yr 
was considered a realistic outcome, in view of the fact 
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that the hospital had previously recorded extremely 
poor rates and did not have any culture facilities. 
Secondary outcomes 
These included: (a) fall in ESR, (b) decrease in 
tuberculosis-associated mortality, (c) resolution of 
chest X-ray, (d) fall in % agalactosyl IgG, (e) weight 
change from values at diagnosis, (f) resolution of 
presenting clinical signs and symptoms. 
INTERVENTION 
The immunotherapy consisted of an autoclaved 
suspension of 10 mg wet weight M. vaccae NCTC 
11659 ml - ’ of M/15 borate-buffered saline pH 8.0 
(10). This was stored at +4”C, and the 0.1 ml dose 
of suspension was injected intradermally over the 
deltoid muscle. Normal saline was used as placebo 
and similarly administered. 
Randomization was achieved by drawing a card 
from a black bag. Intradermal injection of immuno- 
therapy was given after 1 (n = 57), 2 (n = 26) or 3 (n = 7) 
weeks of chemotherapy, and similar numbers of 
patients received injections of saline. It was realized 
from the beginning that follow-up would be difficult, 
and that far more patients would enter the study than 
could be expected to be followed-up. 
FOLLOW-UP 
When possible, l-2 weeks after intervention, 
patients were examined and weighed, second blood 
samples were obtained for ESR and serology, and 
sputa were taken for microscopy (see results). It is 
also the routine practice of the hospital to repeat the 
chest X-ray, 1 month after diagnosis if film is avail- 
able, and this was done for 35 of the randomized 
patients seen in the first follow-up in each of the two 
groups. 
Other than occasional attendance as out-patients 
thereafter, patients were not followed-up again until 
December 1991 to April 1992, some l&14 months 
after entering the study. It is therefore not possible to 
be sure of compliance in the interval between the two 
evaluations, a common situation in studies involving 
tuberculosis patients in most parts of Africa. Between 
entry into the study and the final follow-up, serious 
ethnic and religious disturbances occurred in Kano, 
resulting in many people fleeing the city and not 
returning. Without knowing who had received 
immunotherapy or placebo, a small local team of 
medical assistants (led by TA) actively sought the 
named patients in the city, for most of which postal 
addresses do not exist. The fate of 34 who had 
received immunotherapy, and 47 in the placebo 
group were determined, and those living were 
brought to hospital for assessment. This consisted of 
weighing, clinical examination, sputum examination 
for acid-fast bacilli, and obtaining a final blood 
sample for ESR and serology from a proportion of 
the patients. A chest X-ray examination was per- 
formed in 20 of the followed-up patients (eight 
immunotherapy and 12 placebo recipients). Further 
follow-up is unlikely to be possible since most 
patients have either gone back to the rural areas, 
or have relocated elsewhere on account of fear of 
further religious violence. 
BACTERIOLOGY 
This was carried out in the routine way by staff 
who were unaware which patients were in the study, 
or who had received which intervention. Sputum 
samples were obtained on 3 consecutive days at the 
time of first attendance and thereafter, l-2 weeks 
after intervention and at the final follow-up. Smears 
of sputum on microscope slides were heat-fixed and 
stained for acid-fast bacilli by the Ziehl-Neelsen 
method. These were examined microscopically under 
the x 100 objective and recorded as @4+ of 
bacilli. 
SEROLOGY 
Stored sera were examined by ELISA for anti- 
bodies to HIV 1 and 2 (Wellcozyme, Wellcome 
Laboratories, UK) and for the percentage of agal- 
actosyl IgG [Gal(O)] (15). The assay for Gal (0) 
estimates the percentage of IgG which lacks terminal 
galactose from the oligosaccharides situated on the 
CH, domain. It does not measure the total concen- 
tration of this glycoform. The %Gal(O) was corrected 
for age using previously published values (16). The 
assay method and characteristics have been described 
elsewhere (15). Stocks of sera remain for future 
studies. 
STATISTICAL ANALYSIS 
Fisher’s exact test, the Mann-Whitney U-test and 
the paired t-test were used for comparison of the 
difference between means of the immunotherapy and 
placebo groups. 
Results 
Since the results were similar, irrespective of timing 
of the intervention, these are not shown separately. 
FIRST FOLLOW-UP ASSESSMENT 
Of the 142 patients who returned for assessment 
l-2 weeks after injection (Table l), 77/90 (85.5%) 
were seen from the immunotherapy group after 
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Table I Results obtained at first follow-up 
Immunotherapy Placebo 
19.8 f 8.3 days 20 f I.3 days 
of chemotherapy of chemotherapy 
Increase in 2.90 f 0.24 p<o.o01* 0.55 f 0.17 
body weight (?l=77) (n=65) 
Paired t-test P<O.OOl n.s. 
Mean fall 25.4 f 2.50 p<o.o01* 4.0 f 2.9 
in ESR (n=77) (n=63)§ 
Paired r-test P<0~0001 n.s. 
Sputum still 201753 (26.6?‘0) P<0~00001~ 53165 (82X) 
+ve for AFB 
Change in O/;IGal(O) 3.61 i 0.91 p<o.o5* +0.11 f 1.35 
(n=28) (n= 17) 
Paired l-test P<O~OOO5 ns. 
*Mann-Whitney U-test, tFisher’s exact test, $Two patients with missing sputum results 
excluded, §Two patients with missing ESR results excluded. 
means of 19.8 k 8.3 days since starting chemo- 
therapy, and 9.0 f 56 days since intervention (range 
4-34 days). From the placebo group, 65/90 (72%) 
were seen after 20 f 7.3 days of chemotherapy, and 
12.5 f 6.8 days since intervention (range 6-30 days). 
Thus, both the duration and type of chemotherapy 
received by the two groups were the same at this first 
assessment (daily SHRZ). At this time, four patients 
among the placebo recipients had already died whilst 
in hospital. 
lo-14 MONTH FOLLOW-UP, AND MORTALITY 
At the lo-14 month follow-up, 47 (52%) of the 
placebo group were located, whether live (31%) or 
dead. Four of this group had died while in hospital, 
and 15 more deaths were established, giving a total of 
19 deaths amongst the 47 traced, equivalent to 40% 
mortality. Since there were originally 90 patients in 
this group, the recorded mortality rate, if by chance 
all dead patients were located, is 19/90, or 21%. Even 
this recorded mortality rate is in striking contrast 
to the findings in the immunotherapy group. Of 
this group, 34 (37%) were traced, and no patient 
amongst the immunotherapy recipients had died. The 
survivors traced in each group (28 placebo and 
34 immunotherapy recipients) were re-examined. 
CLINICAL ASSESSMENT 
At diagnosis, all patients had the signs and symp- 
toms of severe tuberculosis, 18 of them with pleural 
effusions (10 in the immunotherapy group). The 
majority of the patients had palpable, and sometimes 
matted cervical lymph nodes, but only 31 had gener- 
alized lymphadenopathy (17 in the immunotherapy 
group). None of the patients had lupus vulgaris. 
Splenomegaly was present in 43 patients and 18 
had mild-moderate hepatomegaly (19 and 11 
respectively, in the immunotherapy group); these are 
common findings in a region where malaria and 
many other infections are endemic. 
At the 10-14 month follow-up, the group receiving 
immunotherapy showed abatement of fever, little or 
no residual cough, resolution of lymph nodes (even in 
those found to be seropositive for HIV), no chest 
pain, and a general improvement in well-being. 
Among the 34 patients in the immunotherapy group, 
three had pleural effusion, two had generalized 
lymphadenopathy, eight had splenomegaly and one 
had hepatomegaly. On the other hand, most of the 
placebo recipients had persistence of clinical features 
of tuberculosis, which often included persistent 
pleuritic pain, fever and productive cough with 
sputum occasionally bloodstained. Of the 28 patients 
followed-up in the placebo group, six had pleural 
effusions, 10 had generalized lymphadenopathy, 18 
had splenomegaly and five had hepatomegaly; signifi- 
cantly more with lymphadenopathy (P<O.O04) and 
splenomegaly (PcO.002) than the immunotherapy 
group. 
On auscultation, the immunotherapy recipients 
had improved air entry, and only occasional basal 
crepitations, whereas the placebo group, in general, 
still had signs of diminished air entry and multiple 
coarse crepitations all over the lung fields. 
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Table 2 Results obtained at the second follow-up 
Immunotherapy (n = 34) Placebo (n =47) 
Mortality among 
patients traced 
Increase in 
body weight 
Mean fall 
in ESR 
Sputum still 
+ve for AFB 
o/34 (0%) 
7.91 kg 
(n=33) 
42 mm 
(n=33) 
11133 (33%) 
19/47 (40%) 
2.04 kg 
(n=26) 
14.96 mm 
(n=26) 
22126 (84.6%) 
HIV1 +ve 
Mortality 
Sputum still 
+ve for AFB 
5/34 (14.7%) 9/47 (19.1%) 
015 (OY”) P=o.o3t 619 (67%) 
o/5 (0%) P<O.OlLq 3/3 (100%) 
*Mann-Whitney U-test, TFisher’s exact test. 
BODY WBIGHT 
The mean body weight at the time of diagnosis of 
those receiving immunotherapy was 47.8 f 1.01 kg, 
and of those receiving placebo it was 46.8 f I.05 kg 
(n.s.). After 19.8 f 8.3 days (immunotherapy group) 
and 20 f 7.3 days (placebo group) of chemotherapy, 
these weights had changed to 50.5 f 1.09 kg and 
46.2 & 1.19 kg respectively (P<O.OOl for the differ- 
ence, see Table 1). The paired t-test showed the 
change to be significant in the immunotherapy group 
(P<O.OOOl), but not in the placebo group. By the 
l&14 month follow-up, survivors had a mean weight 
of 57.03 f 1.94 kg in the immunotherapy group, 
and 51.0 & 1.69 kg in the placebo group (P<O.O005 
for the difference); paired t-tests showed the 
weight change to be significant at P<O.OOOl and 
PcO.04 with regard to the initial mean weight of 
immunotherapy recipients and placebo recipients 
respectively. 
CHEMOTHERAPY PURCHASED 
Despite prescribing the same chemotherapy, and 
encouraging its purchase equally, questioning 
patients 10-14 months after treatment revealed 
immunotherapy recipients to have bought chemo- 
therapy for an average of 2.9 months, whereas sur- 
viving placebo recipients bought it for 6.8 months. 
We cannot be sure whether this reflects purchase 
of all drugs prescribed, or just the cheaper ones. 
Furthermore, these drugs would have been taken 
intermittently as the patients would not have been 
able to afford more than a few weeks at a time. All 
patients purchased drugs from local chemist shops. 
We do not know the quality of drugs purchased, an 
important consideration, since more than 50% of the 
available drugs in circulation are counterfeit 
(3,13,14). However, each patient had an equal chance 
of purchasing either fake or genuine drugs. 
SPUTUM SMEAR MICROSCOPY 
All patients were sputum smear positive for acid- 
fast bacilli at the time of diagnosis. After 19.8 ZIZ 8.3 
days of starting chemotherapy, 73% of the patients 
who had received immunotherapy were sputum nega- 
tive. Of those that received the placebo, 19% (12/65) 
were sputum negative after 20 & 7.3 days of chemo- 
therapy. The chemotherapy received was the same 
for both groups. After 10-14 months, 67% (22/33) of 
immunotherapy recipients and 15% (4/26) of placebo 
recipients were smear negative (Table 3). All patients 
who were sputum positive at the last follow-up, were 
also positive at the first follow-up examination. 
ERYTHROCYTE SEDIMENTATION RATE 
At the first follow-up examination after inter- 
vention, patients who had received immunotherapy 
showed a mean fall in ESR of 25.4 & 2.50 mm com- 
pared to that at diagnosis (paired t-test P>O.OOOl). 
In the placebo recipients, a drop in ESR of 
4.0 * 2.29 mm was observed (P<O.OOl for the differ- 
ence between the groups). 
After 10-14 months, the mean fall in ESR since 
diagnosis was 42.0 f 7.85 mm for the immuno- 
therapy group and 14.96 * 8.5 mm for the placebo 
group (P<O.OOl for the difference). 
HIV SEROLOGY 
Other than a pilot number who were tested in 
Kano by the ELAVIA test, the Wellcome HIV 1 test 
and the Division of Virology (UCL Medical School) 
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Table 3 Results of smear microscopy for acid-fast bacilli 
Immunotherapy Placebo 
Sputum 0 
6L 
++ +++ ++++ 0 + ++ +++ ++++ 
At diagnosis (90) 0 267 10 2.2% (90) 52 35 
First follow-up (75) 73.3 22.7 4 0 0% (65) 1: 62 18 
12 1% 
0% 
Second follow-up (33) 66.6 24.2 6.1 3 0% (26) 15 54 19 1; 0% 
The numbers in parentheses are patients’ samples examined at each time (three samples taken on three successive days 
represents one sputum investigation). One M. vaccae recipient and two placebo recipients had missing data. 0, no acid 
fast bacilli seen on microscopy of 100 high power fields; +, scanty acid fast bacilli seen, but less than 1 per high power field; 
+ +, l-9 bacilli seen per high power field; + + +, 10-99 bacilli seen per high power field; + + + +, 100 or more bacilli seen 
per high power field. 
test kit for HIV 2 were applied to the initial sera 
obtained from persons who were followed-up after 
lo-14 months, including those who had died. In the 
immunotherapy group, 5/34 (15%) patients were 
HIV 1 positive and none were HIV 2 positive. Of 
those that received placebo, 9/47 (19%) were HIV 1 
positive and two of these were strongly positive for 
HIV 2 (an analysis of the results for those positive 
for HIV 1 is shown in comparison with those of the 
entire groups in Table 2). None of the five HIV 1 
positive patients who received immunotherapy had 
died, only one of them still had AFB visible in the 
sputum at l&14 months from diagnosis, and all were 
clinically well. In contrast, of the nine HIV 1 sero- 
positive patients who received placebo, six had died, 
and the three survivors (including the two who were 
also HIV 2 seropositive) were all sputum positive 
for AFB and clinically suffering from advanced 
tuberculosis. 
AGALACTOSYL IgG phGAL(O)] 
The difference between the results at diagnosis and 
at the first follow-up after intervention, corrected for 
the patients’ ages, are shown in Table 1. Within 2 
weeks of intervention, the immunotherapy recipients 
already showed a significant fall in %Gal(O) 
(PcO.0005, paired t-test), whereas those in the 
placebo group show no significant change [P<O.OS 
for the difference in %Gal(O) between the placebo 
and immunotherapy groups]. 
Discussion 
Despite the many drawbacks experienced in the 
execution of this study under the adverse conditions 
prevailing in Kano, it is clear from the evidence 
provided that immunotherapy with M. vaccae was 
beneficial to the patients, and we believe resulted in a 
drop in mortality from pulmonary tuberculosis. 
Admittedly the physician in charge (PCO) was aware 
of the type of intervention given to the patients, but 
the patients themselves did not know which interven- 
tion they received. The laboratory tests were carried 
out in a blinded manner, as was the reading of 
X-rays, and these data provided objective support for 
the clinical findings recorded. The physician in charge 
did not participate in finding patients at follow-up, 
and the team finding the patients did not know which 
patient had received which intervention. The prob- 
lems experienced with follow-up were not unex- 
pected, though numbers traced 10-14 months after 
entry were fewer than we had hoped. The poor 
follow-up can be attributed to the lack of any real 
addresses, civic disruptions, and because many 
patients had returned to their homes in villages 
outside the city. 
Hospital data compiled by the Ministry of Health 
in Kano indicate a high mortality rate amongst 
patients diagnosed as having tuberculosis. However, 
these records reflect deaths occurring during hospi- 
talization. Deaths are unregistered in Kano, and 
cultural and religious rites facilitate quick burials, 
usually by relations of the deceased. Thus it is 
difficult to be sure of figures except for those occur- 
ring in hospital or amongst persons reliably traced in 
the l&14 month follow-up. It could be speculated 
that the disproportion in the numbers followed-up in 
the two groups may be attributed to two factors. 
First, many of the deaths recorded in the placebo 
group may have occurred prior to the population 
disturbances, when larger numbers of both groups 
may still have been in the city. Secondly, rapid 
resolution of disease in the immunotherapy recipients 
may have resulted in their being fitter, and more able 
to leave the city than the placebo group. 
Although the percentage of the patients 
followed-up at 10-14 months was low, the propor- 
tion of patients found at the first follow-up, approxi- 
mately 20 days after starting chemotherapy, was 
satisfactory though slightly skewed by the four 
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patients in the placebo group who had died. At this 
time, several parameters indicating benefit from 
immunotherapy were recorded. There was more 
rapid recovery of body weight, disappearance of 
acid-fast bacilli from the sputum, accelerated fall of 
ESR, and a change in agalactosyl IgG. In contrast to 
the slight elevation of %Gal(O) seen in patients 
treated with chemotherapy alone, there was a fall in 
this glycosylation variant in the immunotherapy 
group. This slight elevation in %Gal(O) amongst 
patients who received chemotherapy alone has also 
been seen in patients receiving optimal chemotherapy 
in the UK (17), and shows that the changes occurring 
in the immunotherapy recipients are distinct from 
those that would be expected if they had received 
privileged chemotherapy. All patients had received 
the same type of chemotherapy, available from com- 
mercial drug stores. Agalactosyl IgG has been found 
to be elevated in tuberculosis, rheumatoid arthritis, 
Crohn’s disease, and leprosy during episodes of 
erythema nodosum leprosum (ENL) (15). It is not 
elevated in acute rheumatic fever or in viral infec- 
tions. This would suggest that it is not merely a 
correlate of inflammation or an acute phase response. 
It has been suggested that raised %Gal(O) occurs in 
conditions associated with chronic T-cell mediated 
response and with increased production of cytokines, 
especially IL-6 and TNF-a. 
Chest X-ray examinations were performed by a 
radiologist working at the General Hospital in Kano 
City, who was not aware of which patient had 
received which intervention. He gave a qualitative 
assessment of the chest radiographs of patients seen 
at diagnosis and 1 month after diagnosis. In this 
respect, the extensive radiological evidence of tuber- 
culosis seen at diagnosis (often with cavity forma- 
tion), showed signs of early resolution after 1 month 
of chemotherapy in many of the patients randomly 
selected to receive immunotherapy. By the fmal 
follow-up, when X-ray examinations were performed 
on eight immunotherapy and 12 placebo recipients, 
improvement was much more obvious in the 
immunotherapy recipients, with the radiologist call- 
ing attention to remarkable closure of cavities in five 
patients and marked improvement in three patients 
in that group. At this time in the placebo group, 
radiology showed active progression of disease in 
eight patients with two showing no change and two 
others showing some resolution of apical cavities seen 
at onset. 
The clinical features associated with the active 
intervention, though subjective, were indicative of 
the general trend of accelerated recovery, as shown 
by both fewer cases with lymphadenopathy 
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Fig. I Percentage mortality rates amongst tuberculosis 
patients in Kano State, Nigeria, 19841987. If the % mor- 
tality continued to rise at a similar rate, which is possible in 
view of the upsurge in HIV incidence and the worsening of 
nutritional level and social conditions, it would have 
reached more than 40% by 1992, when this study was 
performed. 
(P<O.O04) and splenomegaly (P<O.O02), and by 
the objective criteria of changes in weight and ESR, 
and disappearance of acid-fast bacilli from the 
sputum. 
The patients’ own assessments of their well-being is 
reflected in the duration of chemotherapy purchased. 
Although both groups were equally encouraged to 
buy treatment, survivors of the placebo group bought 
at least some drugs for, on average, twice as long as 
immunotherapy recipients did. Of course, we do not 
know how much chemotherapy was bought by those 
who died. Thus, it is even more significant that 
despite more intensive chemotherapy, 85% of the 
placebo group still had AFB visible in their sputum 
10-14 months after entry into the trial. 
The extremely poor results obtained with chemo- 
therapy alone (placebo group) may be attributed to 
two factors (18). First, these patients may have taken 
intermittent doses of the cheaper drugs (streptomycin 
and isoniazid), rather than what was prescribed. 
Secondly, it is well documented that 50-70% of the 
drugs available for purchase in Kano are adulterated, 
out of date, or fake (3,13,14). It is striking that these 
deficiencies were made good by immunotherapy. The 
poor results obtained in the placebo group are not 
improbable for this part of Africa. Until 1987, the 
Kano State Infectious Diseases Hospital (IDH) kept 
statistics for deaths from tuberculosis and when the 
last few years of these are projected to 1992 (assum- 
ing the mortality rate continued to increase at the 
same rate), the expected mortality would be 40% 
(Fig. 1). Moreover, this projected figure is not cor- 
rected for excess mortality attributed to the rapid 
increase in HIV over the same period. 
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Despite the apparent advantages of immuno- 
therapy, 33% smear-positivity 1 yr after diagnosis is 
hardly acceptable and unfortunately, there are no 
culture facilities available for mycobacteria in Kano. 
A study recently carried out in Lagos (19) on patients 
who remained sputum positive after at least 6 months 
of chemotherapy, reported a 56% prevalence of 
resistance to one or more drugs (isoniazid 38%, 
streptomycin 13%, rifampicin 2% and ethambutol 
3%). Other studies with M. vaccue suggest that more 
than one dose may be necessary for the treatment of 
patients infected with drug-resistant bacilli (20). 
Thus, it is possible that those patients who remained 
smear positive (33%) were infected with drug- 
resistant strains. In support of this conclusion, the 11 
patients making up the 33% were sputum positive at 
all three assessments, suggesting that they may have 
been harbouring resistant bacilli from the beginning. 
The data suggest that beneficial effects of immuno- 
therapy occur within the first 2 weeks or so of its 
injection, and that patients with persisting sputum 
positivity beyond this time might benefit from a 
second dose. We hope to explore this possibility in 
studies currently starting. 
The number of patients co-infected with HIV 1 or 
HIV 2 was more than expected, particularly in a 
country with historically low seroprevalance rates 
for HIV (21) in comparison with the rest of the 
African continent. Even with these small numbers, 
survival was significantly better in the immuno- 
therapy recipients, with patients doing just as well as 
the HIV negative patients (22). 
In earlier studies, 1 month (9,lO) or 6 weeks of 
chemotherapy was given before immunotherapy with 
M. vaccae. This was to enable the numbers of live 
bacteria to be substantially reduced before attempt- 
ing an immunological manipulation. Our data show- 
ing that the injection is just as effective when given 
after 1, 2 or 3 weeks of chemotherapy, suggests that 
the wait may not be necessary. Since survival seems 
to be a parameter improved by immunotherapy, 
there are obvious advantages in giving it as soon as 
possible. 
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